[go: up one dir, main page]

MX2015007940A - Compuestos tricíclicos como inhibidores de cftr. - Google Patents

Compuestos tricíclicos como inhibidores de cftr.

Info

Publication number
MX2015007940A
MX2015007940A MX2015007940A MX2015007940A MX2015007940A MX 2015007940 A MX2015007940 A MX 2015007940A MX 2015007940 A MX2015007940 A MX 2015007940A MX 2015007940 A MX2015007940 A MX 2015007940A MX 2015007940 A MX2015007940 A MX 2015007940A
Authority
MX
Mexico
Prior art keywords
tricyclic compounds
cftr inhibitors
present
cftr
inhibitors
Prior art date
Application number
MX2015007940A
Other languages
English (en)
Inventor
Jeffrey Mckenna
Alexander Ashall-Kelly
Louisa Gueritz
Joseph Mckenna
Simon Mutton
Rakesh Parmar
Jon Shepherd
Paul Wright
Mahbud Ahmed
Graham Charles Bloomfield
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2015007940A publication Critical patent/MX2015007940A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto de la fórmula I o una sal farmacéuticamente aceptable del mismo; (ver fórmula) y sus usos terapéuticos. La presente invención proporciona además una combinación de los agentes farmacológicamente activos y una composición farmacéutica.
MX2015007940A 2012-12-19 2013-12-17 Compuestos tricíclicos como inhibidores de cftr. MX2015007940A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261739337P 2012-12-19 2012-12-19
US201361906154P 2013-11-19 2013-11-19
PCT/IB2013/061041 WO2014097147A1 (en) 2012-12-19 2013-12-17 Tricyclic compounds as cftr inhibitors

Publications (1)

Publication Number Publication Date
MX2015007940A true MX2015007940A (es) 2016-03-11

Family

ID=50030371

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007940A MX2015007940A (es) 2012-12-19 2013-12-17 Compuestos tricíclicos como inhibidores de cftr.

Country Status (15)

Country Link
US (1) US9303035B2 (es)
EP (1) EP2935277B1 (es)
JP (1) JP6284545B2 (es)
KR (1) KR20150095925A (es)
CN (1) CN105008370B (es)
AR (1) AR094123A1 (es)
AU (1) AU2013365827A1 (es)
BR (1) BR112015014433A2 (es)
CA (1) CA2895656A1 (es)
EA (1) EA201591175A1 (es)
ES (1) ES2650372T3 (es)
MX (1) MX2015007940A (es)
TW (1) TW201429976A (es)
UY (1) UY35209A (es)
WO (1) WO2014097147A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9056867B2 (en) 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
EP2935278B1 (en) * 2012-12-19 2017-03-15 Novartis AG Tricyclic compounds for inhibiting the cftr channel
KR20150095925A (ko) 2012-12-19 2015-08-21 노파르티스 아게 Cftr 억제제로서의 트리시클릭 화합물
JP6938510B2 (ja) 2015-12-24 2021-09-22 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｃｆｔｒ制御因子及びこの使用方法
CN108699040B (zh) 2015-12-24 2021-08-10 加利福尼亚大学董事会 Cftr调节剂及其使用方法
US11839616B2 (en) 2017-08-24 2023-12-12 The Regents Of The University Of California Ocular pharmaceutical compositions
CN112724157B (zh) * 2021-01-23 2022-04-19 中国科学院新疆理化技术研究所 二氢噁唑并[5,4-d]吡咯并[1,2-a]嘧啶-9(5H)-酮类衍生物及用途
AU2022265718A1 (en) 2021-04-29 2023-11-02 Novartis Ag Deubiquitinase-targeting chimeras and related methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224974B (es) * 1991-07-02 1994-06-11 Hoffmann La Roche
CA2382528A1 (en) 1999-08-25 2001-03-01 Banyu Pharmaceutical Co., Ltd. Novel isoindole derivatives
JP2002255967A (ja) 2001-02-27 2002-09-11 Banyu Pharmaceut Co Ltd イソインドール誘導体を有効成分とする糖尿病の治療剤、糖尿病の慢性合併症の予防剤又は肥満の治療剤。
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
MX2009006228A (es) 2006-12-12 2009-06-22 Schering Corp Inhibidores de aspartil proteasa.
US20110015137A1 (en) * 2007-07-05 2011-01-20 Trustees Of Boston University Reca inhibitors and their uses as microbial inhibitors or potentiators of antibiotic activity
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
IN2012DN00719A (es) * 2009-08-10 2015-06-19 Univ California
USRE48842E1 (en) * 2011-05-27 2021-12-07 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
EP2935278B1 (en) * 2012-12-19 2017-03-15 Novartis AG Tricyclic compounds for inhibiting the cftr channel
KR20150095925A (ko) 2012-12-19 2015-08-21 노파르티스 아게 Cftr 억제제로서의 트리시클릭 화합물

Also Published As

Publication number Publication date
WO2014097147A1 (en) 2014-06-26
CA2895656A1 (en) 2014-06-26
BR112015014433A2 (pt) 2017-07-11
JP6284545B2 (ja) 2018-02-28
CN105008370A (zh) 2015-10-28
AU2013365827A1 (en) 2015-07-09
TW201429976A (zh) 2014-08-01
UY35209A (es) 2014-07-31
AR094123A1 (es) 2015-07-08
JP2016507498A (ja) 2016-03-10
EP2935277B1 (en) 2017-08-30
US20140171412A1 (en) 2014-06-19
ES2650372T3 (es) 2018-01-18
US9303035B2 (en) 2016-04-05
CN105008370B (zh) 2017-06-09
EA201591175A1 (ru) 2015-11-30
KR20150095925A (ko) 2015-08-21
EP2935277A1 (en) 2015-10-28

Similar Documents

Publication Publication Date Title
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
PH12016500072A1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
IN2015DN00185A (es)
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
TN2016000115A1 (en) Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors.
IN2014DN10670A (es)
MX2015007940A (es) Compuestos tricíclicos como inhibidores de cftr.
PH12014502462A1 (en) Complement pathway modulators and uses thereof
MX2020011652A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
MX2015008975A (es) Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn).
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
PH12015501386A1 (en) Tricyclic compounds
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
GB201209587D0 (en) Therapeutic compounds
MX340574B (es) Imidazo pirazinas.
TN2014000060A1 (en) Benzothiazolone compound
MX2016013561A (es) Activadores de herg policiclicos.
TN2014000077A1 (en) Pyridazinone compounds and their use as daao inhibitors
UA110834C2 (uk) Сполука-інгібітор сигнального шляху notch